Argos Therapeutics Company Profile (NASDAQ:ARGS)

About Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics logoArgos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $18.98 million
  • Outstanding Shares: 41,351,000
Average Prices:
  • 50 Day Moving Avg: $0.44
  • 200 Day Moving Avg: $2.82
  • 52 Week Range: $0.31 - $9.22
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.46
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $904,298.00
  • Price / Sales: 20.99
  • Book Value: ($0.33) per share
  • Price / Book: -1.38
Profitability:
  • EBIDTA: ($48,810,000.00)
  • Net Margins: -6,452.34%
  • Return on Assets: -88.70%
Debt:
  • Debt-to-Equity Ratio: 1.81%
  • Current Ratio: 2.98%
  • Quick Ratio: 2.98%
Misc:
  • Average Volume: 1.17 million shs.
  • Beta: 2.1
  • Short Ratio: 2.5
 

Frequently Asked Questions for Argos Therapeutics (NASDAQ:ARGS)

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc (NASDAQ:ARGS) announced its quarterly earnings results on Wednesday, August, 10th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.05. The company earned $0.49 million during the quarter, compared to analyst estimates of $0.16 million. View Argos Therapeutics' Earnings History.

Where is Argos Therapeutics' stock going? Where will Argos Therapeutics' stock price be in 2017?

4 equities research analysts have issued 12-month target prices for Argos Therapeutics' shares. Their forecasts range from $1.20 to $11.00. On average, they expect Argos Therapeutics' share price to reach $5.85 in the next twelve months. View Analyst Ratings for Argos Therapeutics.

What are analysts saying about Argos Therapeutics stock?

Here are some recent quotes from research analysts about Argos Therapeutics stock:

  • 1. According to Zacks Investment Research, "Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. " (5/15/2017)
  • 2. Stifel Nicolaus analysts commented, "Argos reported 4Q16 numbers that included a net loss of $15.4 million and a cash & cash equivalents balance of $53.0 million. This is a time of transition for the company as last month, the IDMC recommended Argos discontinue their Phase III trial of AGS-003 in mRCC (ADAPT) based on futility. The trial is still ongoing while the company is reviewing preliminary data and determining the path forward. In the meantime, the company is reducing its workforce in an effort to conserve cash. However, since quarter's end, one of the company's lenders called its outstanding $23.1 million loan so Argos' current cash balance is closer to about $30 million. As a result of the reduced cash position, we are decreasing our target price from $1.40 to $1.20." (3/17/2017)
  • 3. FBR & Co analysts commented, "On the morning of February 22, Argos Therapeutics announced that the Independent Data Monitoring Committee (IDMC) recommended that the company’s pivotal Phase III ADAPT clinical trial of rocapuldencel-T (AGS-003) in combination with sunitinib (standard therapy) for the treatment of metastatic renal cell carcinoma (mRCC) be discontinued for futility based on its planned interim data analysis. The IDMC came to a conclusion that the study was unlikely to demonstrate a statistically significant improvement in overall survival (OS) in the combination treatment arm of rocapuldencel-T and sunitinib. The company is in the process of analyzing preliminary data from the trial, and its next steps involve discussing the data with the FDA." (2/23/2017)
  • 4. Needham & Company LLC analysts commented, "Argos announced that the pivotal Phase III ADAPT trial of rocapuldencel-T (AGS-003) in renal cell carcinoma (RCC) reached futility at a pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has recommended discontinuation of the trial. Argos plans to leave the trial open pending further data review and FDA discussion, however, we view the likelihood of approval in RCC, our main valuation driver, as too uncertain. We are downgrading shares to Neutral." (2/22/2017)

Are investors shorting Argos Therapeutics?

Argos Therapeutics saw a increase in short interest in April. As of April 28th, there was short interest totalling 2,344,132 shares, an increase of 18.1% from the April 13th total of 1,984,919 shares. Based on an average daily volume of 2,019,414 shares, the days-to-cover ratio is currently 1.2 days.

Who are some of Argos Therapeutics' key competitors?

Who owns Argos Therapeutics stock?

Argos Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FORARGOS B.V. (20.45%) and Vanguard Group Inc. (0.00%). Company insiders that own Argos Therapeutics stock include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom. View Institutional Ownership Trends for Argos Therapeutics.

Who bought Argos Therapeutics stock? Who is buying Argos Therapeutics stock?

Argos Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Argos Therapeutics stock in the last two years include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom. View Insider Buying and Selling for Argos Therapeutics.

How do I buy Argos Therapeutics stock?

Shares of Argos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Argos Therapeutics stock cost?

One share of Argos Therapeutics stock can currently be purchased for approximately $0.46.

Analyst Ratings

Consensus Ratings for Argos Therapeutics (NASDAQ:ARGS) (?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $5.85 (1,174.51% upside)

Analysts' Ratings History for Argos Therapeutics (NASDAQ:ARGS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/19/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$2.00 -> $1.20HighView Rating Details
3/17/2017Stifel NicolausLower Price TargetHold$1.20HighView Rating Details
2/22/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
2/22/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
6/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$11.00N/AView Rating Details
4/19/2016Roth CapitalBoost Price TargetBuy$11.00 -> $18.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$17.00 -> $12.00N/AView Rating Details
6/9/2015MLV & Co.Set Price TargetBuy$13.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Argos Therapeutics (NASDAQ:ARGS)
Earnings by Quarter for Argos Therapeutics (NASDAQ:ARGS)
Earnings History by Quarter for Argos Therapeutics (NASDAQ:ARGS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q3 2016($0.35)($0.32)$0.35 million$0.15 millionViewN/AView Earnings Details
8/10/2016Q2($0.43)($0.48)$0.16 million$0.49 millionViewListenView Earnings Details
5/12/2016Q1($0.56)($0.57)$0.10 million$0.15 millionViewListenView Earnings Details
3/29/2016Q4($0.88)($0.84)$1.12 million$0.07 millionViewListenView Earnings Details
11/16/2015Q315($0.92)($0.97)$0.12 million$0.16 millionViewListenView Earnings Details
8/12/2015Q215($0.80)($0.95)$1.32 million$0.11 millionViewListenView Earnings Details
5/14/2015Q115($0.81)($0.89)$0.40 million$0.18 millionViewListenView Earnings Details
3/30/2015Q314($0.78)($0.83)$0.62 million$0.30 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.65)($0.77)$0.80 million$0.40 millionViewN/AView Earnings Details
8/13/2014Q214($0.60)($0.61)$1.27 million$1.26 millionViewN/AView Earnings Details
5/13/2014Q114($0.54)($1.05)$1.26 million$0.80 millionViewN/AView Earnings Details
3/27/2014Q4 2013($3.42)($36.19)$2.60 million$0.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Argos Therapeutics (NASDAQ:ARGS)
2017 EPS Consensus Estimate: ($1.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.36)($0.36)($0.36)
Q2 20171($0.32)($0.32)($0.32)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Argos Therapeutics (NASDAQ:ARGS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Argos Therapeutics (NASDAQ:ARGS)
Insider Ownership Percentage: 61.64%
Institutional Ownership Percentage: 15.25%
Insider Trades by Quarter for Argos Therapeutics (NASDAQ:ARGS)
Institutional Ownership by Quarter for Argos Therapeutics (NASDAQ:ARGS)
Insider Trades by Quarter for Argos Therapeutics (NASDAQ:ARGS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/7/2016International S PharmstandardMajor ShareholderBuy31,704$4.73$149,959.92View SEC Filing  
9/29/2016International S PharmstandardMajor ShareholderBuy43,618$4.56$198,898.08View SEC Filing  
9/20/2016International S PharmstandardMajor ShareholderBuy41,259$4.77$196,805.43View SEC Filing  
9/19/2016International S PharmstandardMajor ShareholderBuy5,580$4.76$26,560.80View SEC Filing  
9/16/2016International S PharmstandardMajor ShareholderBuy52,512$4.77$250,482.24View SEC Filing  
9/1/2016International S PharmstandardMajor ShareholderBuy16,977$4.78$81,150.06View SEC Filing  
8/24/2016International S PharmstandardMajor ShareholderBuy67,371$4.52$304,516.92View SEC Filing  
8/22/2016International S PharmstandardMajor ShareholderBuy75,474$4.24$320,009.76View SEC Filing  
12/16/2015Andrei Vladimirovich PetrovDirectorBuy5,000$1.80$9,000.00View SEC Filing  
12/16/2015Joan WinterbottomInsiderBuy250$1.83$457.50View SEC Filing  
12/15/2015Alexey Alexandrovic VinogradovDirectorBuy2,000$2.15$4,300.00View SEC Filing  
12/2/2015Jeffrey D AbbeyCEOBuy1,000$3.89$3,890.00View SEC Filing  
11/24/2015Holle Philippe Marie Marce VanDirectorBuy10,000$4.28$42,800.00View SEC Filing  
9/3/2015Holle Philippe Marie Marce VanDirectorBuy12,000$6.27$75,240.00View SEC Filing  
9/1/2015Holle Philippe Marie Marce VanDirectorBuy5,000$6.26$31,300.00View SEC Filing  
8/25/2015Jean LamarreDirectorBuy2,500$6.14$15,350.00View SEC Filing  
8/19/2015Jeffrey D AbbeyCEOBuy5,500$4.75$26,125.00View SEC Filing  
2/12/2014Deventer Sander VanDirectorBuy36,416$8.00$291,328.00View SEC Filing  
2/12/2014International S PharmstandardMajor ShareholderBuy1,275,000$8.00$10,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Argos Therapeutics (NASDAQ:ARGS)
Latest Headlines for Argos Therapeutics (NASDAQ:ARGS)
Source:
DateHeadline
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 15 at 4:28 PM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 15 at 8:48 AM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 12 at 10:58 PM
streetinsider.com logoArgos Therapeutics (ARGS) Offers Update on ADAPT Trial Following Meeting with FDA
www.streetinsider.com - May 11 at 4:02 PM
streetinsider.com logoArgos Therapeutics (ARGS) Offers Update on ADAPT Trial Following Meeting with FDA - StreetInsider.com
www.streetinsider.com - May 10 at 8:51 PM
globenewswire.com logoArgos Provides Update on its ADAPT Trial Following Meeting with FDA - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:13 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Argos Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline
finance.yahoo.com - May 9 at 8:38 PM
finance.yahoo.com logoArgos Therapeutics faces threat of delisting
finance.yahoo.com - May 5 at 3:38 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) Receives Media Impact Rating of 0.30
www.americanbankingnews.com - May 3 at 7:24 PM
americanbankingnews.com logoZacks Investment Research Upgrades Argos Therapeutics Inc (ARGS) to "Buy"
www.americanbankingnews.com - May 2 at 7:16 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) Receives Daily Media Impact Score of -0.10
www.americanbankingnews.com - April 29 at 10:52 AM
americanbankingnews.com logoArgos Therapeutics (ARGS) Receiving Somewhat Negative News Coverage, Report Finds
www.americanbankingnews.com - April 26 at 2:54 PM
finance.yahoo.com logoRobbins Arroyo LLP Reminds Investors of Lead Plaintiff Deadline in Argos Therapeutics, Inc. (ARGS) Class Action - Yahoo Finance
finance.yahoo.com - April 24 at 3:38 PM
finance.yahoo.com logoRobbins Arroyo LLP Reminds Investors of Lead Plaintiff Deadline in Argos Therapeutics, Inc. (ARGS) Class Action
finance.yahoo.com - April 24 at 3:38 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) Getting Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 23 at 10:17 AM
businesswire.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in Argos ...
www.businesswire.com - April 22 at 10:31 AM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Argos Therapeutics Inc's Q1 2017 Earnings (ARGS)
www.americanbankingnews.com - April 21 at 8:57 AM
finance.yahoo.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in Argos Therapeutics, Inc. to Contact the Firm
finance.yahoo.com - April 20 at 8:42 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) Getting Somewhat Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 20 at 2:40 PM
seekingalpha.com logoArgos Therapeutics (ARGS) Presents Interim Analysis Of ADAPT Trial - Slideshow
seekingalpha.com - April 20 at 1:43 AM
benzinga.com logoMid-Day Market Update: Dow Turns Negative; Argos Therapeutics Shares Spike Higher - Benzinga
www.benzinga.com - April 19 at 3:40 PM
streetinsider.com logoArgos Therapeutics (ARGS) Announces Interim Results of ADAPT Trial; to Continue Trial - StreetInsider.com
www.streetinsider.com - April 19 at 3:40 PM
nasdaq.com logoARGS Gets New Lease Of Life, RARE Surges On Study Results, NVLS Abuzz
www.nasdaq.com - April 19 at 8:46 AM
streetinsider.com logoArgos Therapeutics (ARGS) Announces Interim Results of ADAPT Trial; to Continue Trial
www.streetinsider.com - April 19 at 8:46 AM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Given New $1.20 Price Target at FBR & Co
www.americanbankingnews.com - April 19 at 7:28 AM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Short Interest Update
www.americanbankingnews.com - April 15 at 7:08 AM
americanbankingnews.com logoArgos Therapeutics (ARGS) Given Daily Media Sentiment Rating of 0.10
www.americanbankingnews.com - April 14 at 4:42 PM
globenewswire.com logoThe Klein Law Firm Announces a Class Action Has Been Filed on Behalf of Argos Therapeutics, Inc. Shareholders and ... - GlobeNewswire (press release)
globenewswire.com - April 13 at 3:49 PM
finance.yahoo.com logoETFs with exposure to Argos Therapeutics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 8:39 PM
finance.yahoo.com logoARGS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Argos Therapeutics, Inc. and a Lead Plaintiff Deadline of May 15, 2017
finance.yahoo.com - April 3 at 9:07 PM
americanbankingnews.com logoBrokerages Set Argos Therapeutics Inc (ARGS) Target Price at $10.07
www.americanbankingnews.com - March 30 at 10:01 AM
prnewswire.com logoLifshitz & Miller LLP Announces Investigation of Argos Therapeutics, Inc., Avid Technology, Inc., HMS Holdings Corp ... - PR Newswire (press release)
www.prnewswire.com - March 24 at 9:04 PM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 24 at 8:43 PM
biz.yahoo.com logoARGOS THERAPEUTICS INC Files SEC form 8-K, Termination of a Material Definitive Agreement
biz.yahoo.com - March 23 at 9:04 PM
bizjournals.com logoArgos receives termination notice for Centennial Campus lease
www.bizjournals.com - March 23 at 9:04 PM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 23 at 1:05 PM
americanbankingnews.com logoStifel Nicolaus Cuts Argos Therapeutics Inc (ARGS) Price Target to $1.20
www.americanbankingnews.com - March 23 at 10:34 AM
finance.yahoo.com logoIMPORTANT ARGOS THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Argos Therapeutics, Inc. in the Middle District of North Carolina
finance.yahoo.com - March 22 at 9:11 PM
globenewswire.com logoARGS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class ... - GlobeNewswire (press release)
globenewswire.com - March 21 at 9:02 PM
globenewswire.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100000 ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 10:06 PM
businesswire.com logoRobbins Arroyo LLP: Argos Therapeutics, Inc. (ARGS) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - March 16 at 10:06 PM
feeds.benzinga.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Argos Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
feeds.benzinga.com - March 16 at 12:38 PM
biz.yahoo.com logoARGOS THERAPEUTICS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors or
biz.yahoo.com - March 9 at 9:11 PM
bizjournals.com logoArgos to reduce workforce by nearly 40 percent
www.bizjournals.com - March 9 at 9:11 PM
prnewswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - February 28 at 10:13 AM
seekingalpha.com logoArgos Therapeutics: What's In Store After ADAPT's Failure? - Seeking Alpha
seekingalpha.com - February 28 at 10:13 AM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos Therapeutics ... - Business Wire (press release)
www.businesswire.com - February 23 at 1:41 AM
us.rd.yahoo.com logoArgos Therapeutics downgraded by FBR & Co. and JMP Securities
us.rd.yahoo.com - February 22 at 8:40 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos Therapeutics, Inc.
finance.yahoo.com - February 22 at 8:40 PM
benzinga.com logo18 Biggest Mid-Day Losers For Wednesday - Benzinga
www.benzinga.com - February 22 at 3:38 PM

Social

Chart

Argos Therapeutics (ARGS) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff